Pulmonary infection with mycobacterium xenopi: review of treatment and response. 1984

J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith

Forty seven patients (82% male) with pulmonary infection caused by Mycobacterium xenopi have been reviewed. Pre-existing lung disease was present in 35 (75%). In 21 patients the disease was characterised by a subacute illness developing over a period of two to four months, while in another 20 patients there was a longer history of chronic respiratory problems often associated with slowly progressive changes evident from chest radiographs. Response to treatment was poor and unpredictable, and was not related to the results of in vitro sensitivity tests, pre-existing lung disease, or mode of onset of symptoms. Eleven patients (23%) were cured with chemotherapy. The best drug regimen appeared to be rifampicin and isoniazid combined with either streptomycin or ethambutol. Another 12 (26%) showed favourable responses to drug treatment initially, but eventually relapsed. Four patients had progressive disease while receiving prolonged courses of chemotherapy. Resection was performed in five patients with resultant cure in four. Since the prognosis with drug treatment alone is so unpredictable it is suggested that resection might be part of first line treatment, and that it should usually be performed if patients fail to respond to initial chemotherapy or if they relapse.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009164 Mycobacterium Infections Infections with bacteria of the genus MYCOBACTERIUM. Infections, Mycobacterium,Infection, Mycobacterium,Mycobacterium Infection
D009165 Mycobacterium Infections, Nontuberculous Infections with nontuberculous mycobacteria (atypical mycobacteria): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae, M. leprae. Mycobacterium Infections, Atypical,Atypical Mycobacterial Infection, Disseminated,Atypical Mycobacterial Infection, Familial Disseminated,Atypical Mycobacteriosis, Familial,Atypical Mycobacteriosis, Familial Disseminated,Atypical Mycobacterium Infections,Infections, Atypical Mycobacterium,Mycobacterium abscessus Infection,Atypical Mycobacterium Infection,Familial Atypical Mycobacterioses,Familial Atypical Mycobacteriosis,Infection, Mycobacterium abscessus,Infections, Mycobacterium abscessus,Mycobacterioses, Familial Atypical,Mycobacteriosis, Familial Atypical,Mycobacterium Infection, Atypical,Mycobacterium Infection, Nontuberculous,Mycobacterium abscessus Infections,Nontuberculous Mycobacterium Infection,Nontuberculous Mycobacterium Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
January 1998, Journal of computer assisted tomography,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
December 2001, The Annals of thoracic surgery,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
January 1998, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
September 1994, Internal medicine (Tokyo, Japan),
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
June 2000, Revista clinica espanola,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
August 2003, Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
September 2005, Revue de pneumologie clinique,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
September 1986, Tubercle,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
January 2001, Cutis,
J Banks, and A M Hunter, and I A Campbell, and P A Jenkins, and A P Smith
October 1987, The Journal of nervous and mental disease,
Copied contents to your clipboard!